Focusing on the evolution of disease spectrum, we apply patient demand-oriented precise R&D to meet every individual's diversified needs.
Focusing on the evolution of disease spectrum, we apply patient demand-oriented precise R&D to meet every individual's diversified needs.
We focus on major issues in modernization and internationalization of TCM, and analyzes and plans key technologies for quality management of TCM from three dimensions: design, control and evaluation. We have integrated information technology, system science and engineering, process analysis technology (PAT) and other advanced manufacturing technologies, and built a real-time TCM database. Our annual processing capacity of medicinal materials reaches 12,000 tons. We have the largest domestic modern TCM extraction platform built in accordance with leading international standards. We also have the world’s only cryogenic and liquid-condensed dripping pill production line and a domestically leading digital TCM freeze-dried powder production line. Through system integration and innovation, we have created an advanced modern TCM production platform with process visualization, smart equipment intelligence, and digitalized quality control and management functions. As a benchmark setter in the upgrading of intelligent TCM production technology in China, we are trying to introduce intelligent TCM production to the world.
Possessed with independently developed a mammalian cell cultivation platform that adopts the continuous perfusion process, we are one of the few pharmaceutical companies in China that has achieved large-scale commercialization of this technology.
Owing to rich experiences in cell culture, we have the ability to minimize the degradation of the target protein while maintaining continuous cell culture for up to 120 days. Compared with the batch culture process, the efficiency of continuous perfusion culture is increased by 500% to 1000%.
